pembrolizumab

• 

Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer

By Sharon Deveson Kell|2023-01-24T09:57:36+00:0024 Jan 2023|Drug treatments|

Non-clear cell kidney cancer is a group of different subtypes [...]

Read More

Comments Off on Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer

• 

NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

By Sharon Deveson Kell|2022-11-30T15:29:22+00:0030 Nov 2022|Drug treatments|

The National Institute for Health and Care Excellence (NICE) has [...]

Read More

Comments Off on NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

• 

Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times

By Sharon Deveson Kell|2022-10-27T08:20:36+00:0027 Oct 2022|Drug treatments|

When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]

Read More

Comments Off on Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times

• 

Adjuvant pembrolizumab approved in Scotland

By Sharon Deveson Kell|2022-10-11T09:50:08+00:0011 Oct 2022|Drug treatments|

Yesterday is was announced that the Scottish Medicines Consortium (SMC) [...]

Read More

Comments Off on Adjuvant pembrolizumab approved in Scotland

• 

Adjuvant pembrolizumab approved by NICE

By Sharon Deveson Kell|2022-10-25T08:05:58+00:0026 Sep 2022|Drug treatments|

Late last week we learnt that the National Institute for [...]

Read More

Comments Off on Adjuvant pembrolizumab approved by NICE

• 

ESMO 2022: Pembrolizumab plus lenvatinib shows promise for non clear cell kidney cancer

By Sharon Deveson Kell|2022-10-25T07:38:41+00:0014 Sep 2022|Drug treatments|

The phase 2 KEYNOTE-B61 study was presented at the recent [...]

Read More

Comments Off on ESMO 2022: Pembrolizumab plus lenvatinib shows promise for non clear cell kidney cancer

• 

ESMO 2022: Update of the lenvatinib plus pembrolizumab versus sunitinib study in patients with advanced kidney cancer

By Sharon Deveson Kell|2022-09-14T08:02:43+00:0013 Sep 2022|Drug treatments|

Results from the phase 3 CLEAR studywere presented at the [...]

Read More

Comments Off on ESMO 2022: Update of the lenvatinib plus pembrolizumab versus sunitinib study in patients with advanced kidney cancer

• 

AUA 2022: Should everyone have adjuvant therapy after surgery for high-risk kidney cancer?

By Sharon Deveson Kell|2022-06-28T08:24:52+00:0028 Jun 2022|Drug treatments|

The 2022 American Urological Association (AUA) Annual Meeting included a [...]

Read More

Comments Off on AUA 2022: Should everyone have adjuvant therapy after surgery for high-risk kidney cancer?

• 

Quality of life on lenvatinib plus pembrolizumab combination

By Sharon Deveson Kell|2022-05-17T07:35:28+00:0017 May 2022|Drug treatments|

In this study, the health-related quality of life (HRQoL) of [...]

Read More

Comments Off on Quality of life on lenvatinib plus pembrolizumab combination

• 

Treatment of people who relapse on adjuvant pembrolizumab

By Sharon Deveson Kell|2022-05-03T08:30:19+00:003 May 2022|Drug treatments|

Adjuvant treatment is treatment that is given after surgery to [...]

Read More

Comments Off on Treatment of people who relapse on adjuvant pembrolizumab